NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024

NextCure +6.59% Pre

NextCure

NXTC

1.78

1.78

+6.59%

0.00% Pre

  • Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%

     
  • Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43%
  • Data to be presented June 1, 2024, 9:00 am-12:00 pm CT

     

BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via